2024年5月29日 · A new consensus statement outlines best practices for assessing and managing spasticity across a range of conditions.

This article will review the pharmacology of botulinum toxin type A and its clinical efficacy when used to treat upper limb spasticity after stroke.

Despite the seriousness of botulism, local injections of botulinum toxin type A are well tolerated and serious side effects are rare. Adverse events can be classified as local or systemic. [56 ...

The licensed indications for treatment with botulinum toxin vary between countries. Both Dysport and Botox are licensed for the treatment of spasticity in the UK and much of Europe, but not in …

2016年9月16日 · Arbaclofen extended-release tablets can decrease spasticity related to multiple sclerosis, with a better safety profile than baclofen, new research suggests.

A small uncontrolled study of treatment of upper limb spasticity after stroke reported encouraging benefits, including decreased spasticity, increased range of movement and increased scores …

Spasticity is formally defined as a velocity-dependent increase in resistance to passive range of motion. It is a hallmark of neurological diseases that affect the central nervous system ...

2016年1月26日 · The FDA has approved a new indication for Allergan's Botox (onabotulinumtoxinA): lower limb spasticity seen after stroke and in other neurologic disorders.

Expert Commentary Botulinum toxin is an established treatment for upper limb spasticity after stroke and it should be delivered to meet agreed rehabilitation goals. [ 6] Randomized …

Blockage of transmission of sensory neurotransmitters may explain this independent analgesic effect. [ 19, 24] Two preparations of botulinum toxin type A are used in spasticity management.